Betta Pharmaceuticals Co Ltd
300558
Company Profile
Business description
Betta Pharmaceuticals Co Ltd is a pharmaceutical enterprise that focuses on the research and development of innovative medicines. The company's drug is used for various diseases such as malignant tumors, diabetes, and cardio-cerebrovascular disease. Further, it offers Icotinib hydrochloride, an orally administered small-molecule and a reversible tyrosine kinase inhibitor, which is used for the treatment of non-small-cell lung cancer. Geographically, the group operates in China.
Contact
No. 355, Xingzhong Road
Economic and Technological Development Zone
Yuhang District, Zhejiang Province
Hangzhou311100
CHNT: +86 57189265665
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
1,696
Stocks News & Analysis
stocks
Alibaba fair value increases by 49%
Stronger-than-expected AI demand internationally and domestically.
stocks
A 5-Star US stock to buy with a near-5% yield
Undervalued by 23%, this cheap dividend stock is a top pick in its sector.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,148.50 | 45.40 | 0.50% |
| CAC 40 | 7,890.85 | 20.17 | 0.26% |
| DAX 40 | 23,790.50 | 51.03 | 0.21% |
| Dow JONES (US) | 46,247.29 | 299.97 | 0.65% |
| FTSE 100 | 9,329.36 | 44.53 | 0.48% |
| HKSE | 26,622.88 | 494.68 | 1.89% |
| NASDAQ | 22,484.07 | 99.37 | 0.44% |
| Nikkei 225 | 45,043.75 | 311.24 | -0.69% |
| NZX 50 Index | 13,132.56 | 20.83 | 0.16% |
| S&P 500 | 6,643.70 | 38.98 | 0.59% |
| S&P/ASX 200 | 8,862.80 | 52.10 | 0.59% |
| SSE Composite Index | 3,862.53 | 34.43 | 0.90% |